Product category:
Contract research
News Release from: Millipore | Subject: CardiacProfiler service
Edited by the Laboratorytalk Editorial
Team on 18 April 2007
First L-type calcium channel for drug
testing
This cell line stably expresses three subunits and has been developed and validated to meet biophysical and pharmacological properties of the L-type calcium channel found in the human heart
Millipore has announced the addition of the human L-type calcium channel to its CardiacProfiler Service for compound liability testing Millipore is the first to offer this voltage-gated channel involved in normal myocardial and vascular smooth muscle contractility
This article was originally published on Laboratorytalk on 3 Jul 2008 at 8.00am (UK)
Related stories
Stainless bins for disposable process containers
Mobius stainless steel bins provide support for handling disposable process containers filled with media, buffer, additional intermediates as well as final products
In vivo monitoring of stem cell behaviour
Millipore has announced the availability of its MilliTrace primary rodent neural stem cell (NSC) lines that express green fluorescent protein (GFP) constitutively
A link between hERG channel block, QT prolongation and the ventricular tachyarrhythmia Torsades de Pointes (TdP) has been established, revealing the need to assess the cardiac risk of potential drugs.
Recombinant cell lines that express multiple subunit ion channels are an integral part of testing novel compounds, yet developing these cell lines is complicated.
Millipore has simplified the process by adding the Precision hCav1.2 recombinant cell line to its CardiacProfiler service.
For the L-type calcium channel, the precise timing of opening, inactivation and closing the channel mirrors the coordinated beating of the heart.
Non-cardiovascular drugs should avoid an L-type blocking action at clinically relevant concentrations because such activity may cause cardiac side-effects.
In some cardiovascular drugs with significant hERG block, L-type calcium channel blocking may be beneficial because the mixed-channel block action may not prolong the QT interval, thereby making it a safe drug.
Millipore's CardiacProfiler service offers compound profiling against the L-type calcium channel assessed either as a stand alone service or as part of a panel of other cardiac ion channels, including hERG, Nav1.5, KCNQ1/minK, Kv1.5, Kv4.3/KChIP1 and HCN4.
Millipore offers this critical target in the CardiacProfiler service through a license with Merck. Request a free brochure from Millipore ...
• Millipore: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
